<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Two_Fears_To_Inquire_About_Wee1_inhibitor</id>
		<title>Two Fears To Inquire About Wee1 inhibitor - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=Two_Fears_To_Inquire_About_Wee1_inhibitor"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Two_Fears_To_Inquire_About_Wee1_inhibitor&amp;action=history"/>
		<updated>2026-04-07T15:47:11Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=Two_Fears_To_Inquire_About_Wee1_inhibitor&amp;diff=34052&amp;oldid=prev</id>
		<title>Brakearies94 : Page créée avec « 4%) lobular carcinoma, 73 (1.7%) mucinous carcinoma, 61 (1.4%) papillary carcinoma, 9 (0.2%) medullary carcinoma, and 439 (10.3%) ductal carcinoma in situ (DCIS). Accordin... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=Two_Fears_To_Inquire_About_Wee1_inhibitor&amp;diff=34052&amp;oldid=prev"/>
				<updated>2016-10-27T06:18:25Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « 4%) lobular carcinoma, 73 (1.7%) mucinous carcinoma, 61 (1.4%) papillary carcinoma, 9 (0.2%) medullary carcinoma, and 439 (10.3%) ductal carcinoma in situ (DCIS). Accordin... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;4%) lobular carcinoma, 73 (1.7%) mucinous carcinoma, 61 (1.4%) papillary carcinoma, 9 (0.2%) medullary carcinoma, and 439 (10.3%) ductal carcinoma in situ (DCIS). According to the AJCC 2010 staging system, 1,314 (30.7%) patients were stage I, 1,628 (38.0%) stage II, 668 (15.6%) stage III, and 230 (5.4%) stage IV. The majority of patients, 2,738 (64.0%), did not have nodal metastases. Table 1 Demographic and clinicopathologic characteristics by race. Modified radical mastectomy was performed in 2,424 (56.6%) patients, while 1,027 (24.0%) underwent simple mastectomy, 511 (11.9%) partial mastectomy, 166 (3.9%) no treatment, 59 (1.4%) primary radiotherapy (RT), 41 (1.0%) radical mastectomy, [http://www.selleckchem.com/products/ar-a014418.html AR-A014418 purchase] and 22 (0.5%) nipple-sparing mastectomy. Lymph node dissection was performed in 3,583 (83.7%) patients, and 932 (21.8%) received adjuvant RT. Blacks were more likely to be diagnosed at a younger age when compared with Whites, Hispanics, and Asians (61.2% versus 43.8% versus 59.8% versus 54.0%; P [http://www.selleckchem.com/wee1-kinase.html Wee1 inhibitor] Asians (56.0% versus 64.8% versus 56.9% versus 67.0%; P  were still observed when comparing by age (P [http://en.wikipedia.org/wiki/Cofactor_(biochemistry) Cofactor] stage, there was no difference in receipt of primary treatment with respect to race (Table 2). Table 2 Primary treatment by stage and race. 3.2. Survival Outcome The median follow-up for the whole patient cohort was 54 months (range: 0�C275). The 5-year overall survival rate (OS) for the study population was 73.4%. Patients ��65 years had significantly worse 5-year OS when compared with those&lt;/div&gt;</summary>
		<author><name>Brakearies94</name></author>	</entry>

	</feed>